Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066651 · ClinicalTrials.gov registry record · Phase 1
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00066651: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00066651 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066651, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors. PURPOSE: This phase I trial is studying the side effects and best dose of immunotoxin therapy in treating patients with recurrent unresectable advanced solid tumors.
Interventions
- BIOLOGICAL SS1(dsFv)-PE38 immunotoxin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-07 |
| Phase | Phase 1 |
What the finished NCT00066651 record still lists
NCT00066651 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which SS1(dsFv)-PE38 immunotoxin is the first listed.
NCT00066651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00066651 about?
NCT00066651 is a clinical study titled "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors". RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors. PURPOSE: This phase I trial is studying the side effects and best dose of immunotoxin therapy in treating patients with recurrent unrese...
What is the current status of trial NCT00066651?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-07.
What interventions are being tested in trial NCT00066651?
The interventions under investigation include: SS1(dsFv)-PE38 immunotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00066651?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia